{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:05:48Z","timestamp":1794485148101,"version":"4.9.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"EORTC Quality of Life Group","award":["Grant number 005\/2020"],"award-info":[{"award-number":["Grant number 005\/2020"]}]},{"name":"EORTC Quality of Life Group","award":["Grant number 005\/2020"],"award-info":[{"award-number":["Grant number 005\/2020"]}]},{"name":"EORTC Quality of Life Group","award":["Grant number 005\/2020"],"award-info":[{"award-number":["Grant number 005\/2020"]}]},{"name":"EORTC Quality of Life Group","award":["Grant number 005\/2020"],"award-info":[{"award-number":["Grant number 005\/2020"]}]},{"name":"EORTC Quality of Life Group","award":["Grant number 005\/2020"],"award-info":[{"award-number":["Grant number 005\/2020"]}]},{"name":"EORTC Quality of Life Group","award":["Grant number 005\/2020"],"award-info":[{"award-number":["Grant number 005\/2020"]}]},{"name":"EORTC Quality of Life Group","award":["Grant number 005\/2020"],"award-info":[{"award-number":["Grant number 005\/2020"]}]},{"name":"EORTC Quality of Life Group","award":["Grant number 005\/2020"],"award-info":[{"award-number":["Grant number 005\/2020"]}]},{"name":"EORTC Quality of Life Group","award":["Grant number 005\/2020"],"award-info":[{"award-number":["Grant number 005\/2020"]}]},{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of open-ended questions supplementing static questionnaires with closed questions may facilitate the recognition of symptoms and toxicities. The open-ended \u2018Write In three Symptoms\/Problems (WISP)\u2019 instrument permits patients to report additional symptoms\/problems not covered by selected EORTC questionnaires. We evaluated the acceptability and usefulness of WISP with cancer patients receiving active and palliative care\/treatment in Austria, Chile, France, Jordan, the Netherlands, Norway, Spain and the United Kingdom.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a literature search on validated instruments for cancer patients including open-ended questions and analyzing their responses. WISP was translated into eight languages and pilot tested. WISP translations were pre-tested together with EORTC QLQ-C30, QLQ-C15-PAL and relevant modules, followed by patient interviews to evaluate their understanding about WISP. Proportions were used to summarize patient responses obtained from interviews and WISP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From the seven instruments identified in the literature, only the free text collected from the PRO-CTAE has been analyzed previously. In our study, 161 cancer patients participated in the pre-testing and interviews (50% in active treatment). Qualitative interviews showed high acceptability of WISP. Among the 295 symptoms\/problems reported using WISP, skin problems, sore mouth and bleeding were more prevalent in patients in active treatment, whereas numbness\/tingling, dry mouth and existential problems were more prevalent in patients in palliative care\/treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The EORTC WISP instrument was found to be acceptable and useful for symptom assessment in cancer patients. WISP improves the identification of symptoms\/problems not assessed by cancer-generic questionnaires and therefore, we recommend its use alongside the EORTC questionnaires.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12955-024-02244-z","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T02:22:28Z","timestamp":1711419748000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Acceptability and usefulness of the EORTC \u2018Write In three Symptoms\/Problems\u2019 (WISP): a brief open-ended instrument for symptom assessment in cancer patients"],"prefix":"10.1186","volume":"22","author":[{"given":"Leslye","family":"Rojas-Concha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Ignacio","family":"Arrarr\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Conroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Chalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Guberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Holzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Husson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmara","family":"Kuli\u015b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Shamieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Piccinin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Puga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mogens","family":"Groenvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf the EORTC Quality of Life Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"issue":"4","key":"2244_CR1","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00520-011-1160-6","volume":"20","author":"A Caissie","year":"2012","unstructured":"Caissie A, Culleton S, Nguyen J, Zhang L, Zeng L, Holden L, et al. EORTC QLQ-C15-PAL quality of life scores in patients with advanced cancer referred for palliative radiotherapy. Support Care Cancer. 2012;20(4):841\u20138. https:\/\/doi.org\/10.1007\/s00520-011-1160-6.","journal-title":"Support Care Cancer"},{"issue":"1","key":"2244_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/s1359-6349(12)70023-x","volume":"10","author":"G Velikova","year":"2012","unstructured":"Velikova G, Coens C, Efficace F, Greimel E, Groenvold M, Johnson C, et al. Health-related quality of life in EORTC clinical trials \u2014 30 years of progress from methodological developments to making a real impact on oncology practice. EJC Suppl. 2012;10(1):141\u20139. https:\/\/doi.org\/10.1016\/s1359-6349(12)70023-x.","journal-title":"EJC Suppl"},{"issue":"2","key":"2244_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1634\/theoncologist.7-2-120","volume":"7","author":"A Bottomley","year":"2002","unstructured":"Bottomley A. The cancer patient and quality of life. Oncologist. 2002;7(2):120\u20135. https:\/\/doi.org\/10.1634\/theoncologist.7-2-120.","journal-title":"Oncologist"},{"issue":"5","key":"2244_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2244_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/jnci\/85.5.36510.1016\/j.ejca.2005.06.022","volume":"42","author":"M Groenvold","year":"2006","unstructured":"Groenvold M, Petersen MA, Aaronson NK, Arraras JI, Blazeby JM, Bottomley A, et al. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer. 2006;42(1):55\u201364. https:\/\/doi.org\/10.1093\/jnci\/85.5.36510.1016\/j.ejca.2005.06.022.","journal-title":"Eur J Cancer"},{"issue":"3","key":"2244_CR6","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s11136-013-0511-9","volume":"23","author":"JI Arraras","year":"2014","unstructured":"Arraras JI, de la Vega FA, Asin G, Rico M, Zarandona U, Eito C, et al. The EORTC QLQ-C15-PAL questionnaire: validation study for Spanish bone metastases patients. Qual Life Res. 2014;23(3):849\u201355. https:\/\/doi.org\/10.1007\/s11136-013-0511-9.","journal-title":"Qual Life Res"},{"issue":"6","key":"2244_CR7","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1007\/s00520-015-3018-9","volume":"24","author":"A Alawneh","year":"2016","unstructured":"Alawneh A, Yasin H, Khirfan G, Qayas BA, Ammar K, Rimawi D, et al. Psychometric properties of the Arabic version of EORTC QLQ-C15-PAL among cancer patients in Jordan. Support Care Cancer. 2016;24(6):2455\u201362. https:\/\/doi.org\/10.1007\/s00520-015-3018-9.","journal-title":"Support Care Cancer"},{"issue":"8","key":"2244_CR8","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1177\/1049909118760781","volume":"35","author":"M Gol\u010di\u0107","year":"2018","unstructured":"Gol\u010di\u0107 M, Dobrila-Dintinjana R, Gol\u010di\u0107 G, Pavlovi\u0107-Ru\u017ei\u0107 I, Stevanovi\u0107 A, Govi\u0107-Gol\u010di\u0107 L. Quality of life in a hospice: a validation of the Croatian version of the EORTC QLQ-C15-PAL. Am J Hosp Palliat Med. 2018;35(8):1085\u201390. https:\/\/doi.org\/10.1177\/1049909118760781.","journal-title":"Am J Hosp Palliat Med"},{"issue":"1","key":"2244_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12904-020-00586-1","volume":"19","author":"L Rojas-Concha","year":"2020","unstructured":"Rojas-Concha L, Hansen MB, Petersen MA, Groenvold M. Content validation of the EORTC QLQ-C15-PAL with advanced cancer patients and health care professionals from palliative care services in Chile. BMC Palliat Care. 2020;19(1):1\u201310. https:\/\/doi.org\/10.1186\/s12904-020-00586-1.","journal-title":"BMC Palliat Care"},{"issue":"7","key":"2244_CR10","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1158\/1078-0432.Ccr-15-2035","volume":"22","author":"PG Kluetz","year":"2016","unstructured":"Kluetz PG, Slagle A, Papadopoulos EJ, Johnson LL, Donoghue M, Kwitkowski VE, et al. Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms. Clin Cancer Res. 2016;22(7):1553\u20138. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-2035.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2244_CR11","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s00520-019-04976-x","volume":"28","author":"L Rojas-Concha","year":"2020","unstructured":"Rojas-Concha L, Hansen MB, Petersen MA, Groenvold M. Which symptoms and problems do advanced cancer patients admitted to specialized palliative care report in addition to those included in the EORTC QLQ-C15-PAL? A register-based national study. Support Care Cancer. 2020;28(4):1725\u201335. https:\/\/doi.org\/10.1007\/s00520-019-04976-x.","journal-title":"Support Care Cancer"},{"key":"2244_CR12","unstructured":"Kuli\u015b D, Bottomley A, Velikova G, Greimel E, Koller M. EORTC Quality of Life Group translation procedure. Fourth ed. Eur Organ Res Treat Cancer. 2017. https:\/\/qol.eortc.org\/manual\/translation-procedure\/."},{"key":"2244_CR13","unstructured":"Wheelwright S, Bjordal K, Bottomley A, Gilbert A, Martinelli M, Pe M, et al. EORTC Quality of life group guidelines for developing questionnaire modules. Fifth ed. Eur Organ Res Treat Cancer. 2021. https:\/\/scholar.google.com\/scholar_lookup? title=EORTC+Quality+of+Life+Group+Guidelines+for+Developing+Questionnaire+Modules&author=Wheelwright,+Sally&author=Andrew+Bottomley+Kristin+Bjordal&author=Alexandra+Gilbert&author=Francesca+Sophie+Darlington&author=Peter+Fayers&publication_year=2021."},{"issue":"8","key":"2244_CR14","first-page":"A12200916","volume":"68","author":"L Rojas-Concha","year":"2021","unstructured":"Rojas-Concha L, Petersen MA, Groenvold M. Characteristics of patients reporting symptoms by open-ended questions in specialist palliative care. Dan Med J. 2021;68(8):A12200916.","journal-title":"Dan Med J"},{"issue":"2","key":"2244_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00520-024-08345-1","volume":"32","author":"L Rojas-Concha","year":"2024","unstructured":"Rojas-Concha L, Hansen MB, Groenvold M. Symptoms and problems reported by patients with non-cancer diseases through open-ended questions in specialist palliative care: a national register-based study. Support Care Cancer. 2024;32(2):141. https:\/\/doi.org\/10.1007\/s00520-024-08345-1.","journal-title":"Support Care Cancer"},{"issue":"5","key":"2244_CR16","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00520-005-0009-2","volume":"14","author":"J Homsi","year":"2006","unstructured":"Homsi J, Walsh D, Rivera N, Rybicki LA, Nelson KA, Legrand SB, et al. Symptom evaluation in palliative medicine: patient report vs systematic assessment. Support Care Cancer. 2006;14(5):444\u201353. https:\/\/doi.org\/10.1007\/s00520-005-0009-2.","journal-title":"Support Care Cancer"},{"issue":"2","key":"2244_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/082585979100700202","volume":"7","author":"E Bruera","year":"1991","unstructured":"Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7(2):6\u20139. https:\/\/doi.org\/10.1177\/082585979100700202.","journal-title":"J Palliat Care"},{"issue":"9","key":"2244_CR18","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/0959-8049(94)90182-1","volume":"30","author":"RK Portenoy","year":"1994","unstructured":"Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, et al. The memorial symptom assessment scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30(9):1326\u201336. https:\/\/doi.org\/10.1016\/0959-8049(94)90182-1.","journal-title":"Eur J Cancer"},{"issue":"5","key":"2244_CR19","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/1097-0142(20000901)89:5%3C1162::aid-cncr26%3E3.0.co;2-y","volume":"89","author":"VT Chang","year":"2000","unstructured":"Chang VT, Hwang SS, Feuerman M, Kasimis BS, Thaler HT. The memorial symptom assessment scale short form (MSAS-SF) validity and reliability. Cancer. 2000;89(5):1162\u201371. https:\/\/doi.org\/10.1002\/1097-0142(20000901)89:5%3C1162::aid-cncr26%3E3.0.co;2-y.","journal-title":"Cancer"},{"key":"2244_CR20","doi-asserted-by":"publisher","unstructured":"Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9). https:\/\/doi.org\/10.1093\/jnci\/dju244.","DOI":"10.1093\/jnci\/dju244"},{"issue":"4","key":"2244_CR21","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/jamia\/ocy169","volume":"26","author":"AE Chung","year":"2019","unstructured":"Chung AE, Shoenbill K, Mitchell SA, Dueck AC, Schrag D, Bruner DW, et al. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute\u2019s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). J Am Med Inform. 2019;26(4):276\u201385. https:\/\/doi.org\/10.1093\/jamia\/ocy169.","journal-title":"J Am Med Inform"},{"issue":"11","key":"2244_CR22","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1093\/annonc\/mdx453","volume":"28","author":"M Koller","year":"2017","unstructured":"Koller M, Hjermstad MJ, Tomaszewski KA, Tomaszewska IM, Hornslien K, Harle A, et al. An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients. Ann Oncol. 2017;28(11):2874\u201381. https:\/\/doi.org\/10.1093\/annonc\/mdx453.","journal-title":"Ann Oncol"},{"issue":"8","key":"2244_CR23","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1177\/0269216319854264","volume":"33","author":"FEM Murtagh","year":"2019","unstructured":"Murtagh FEM, Ramsenthaler C, Firth A, Groeneveld EI, Lovell N, Simon ST, et al. A brief, patient-and proxy-reported outcome measure in advanced illness: Validity, reliability and responsiveness of the Integrated Palliative care Outcome Scale (IPOS). Palliat Med. 2019;33(8):1045\u201357. https:\/\/doi.org\/10.1177\/0269216319854264.","journal-title":"Palliat Med"},{"issue":"2","key":"2244_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.annonc.2019.10.027","volume":"31","author":"V Bjelic-Radisic","year":"2020","unstructured":"Bjelic-Radisic V, Cardoso F, Cameron D, Brain E, Kuljanic K, da Costa RA, et al. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45. Ann Oncol. 2020;31(2):283\u20138. https:\/\/doi.org\/10.1016\/j.annonc.2019.10.027.","journal-title":"Ann Oncol"},{"issue":"5","key":"2244_CR25","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1136\/bmjspcare-2019-001880","volume":"51","author":"SA Alsirafy","year":"2016","unstructured":"Alsirafy SA, Abd El-Aal HH, Farag DE, Radwan RH, El-Sherief WA, Fawzy R. High symptom burden among patients with newly diagnosed incurable cancer in a developing country. J Pain Symptom Manage. 2016;51(5):e1\u20135. https:\/\/doi.org\/10.1136\/bmjspcare-2019-001880.","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"2244_CR26","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jval.2013.04.015","volume":"16","author":"NE Rothrock","year":"2013","unstructured":"Rothrock NE, Jensen SE, Beaumont JL, Abernethy AP, Jacobsen PB, Syrjala K, et al. Development and Initial Validation of the NCCN\/FACT symptom index for advanced kidney cancer. Value Health. 2013;16(5):789\u201396. https:\/\/doi.org\/10.1016\/j.jval.2013.04.015.","journal-title":"Value Health"},{"issue":"2","key":"2244_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/jso.23466","volume":"109","author":"B Badgwell","year":"2014","unstructured":"Badgwell B, Bruera E, Klimberg SV. Can patient reported outcomes help identify the optimal outcome in palliative surgery? J Surg Oncol. 2014;109(2):145\u201350. https:\/\/doi.org\/10.1002\/jso.23466.","journal-title":"J Surg Oncol"},{"issue":"4","key":"2244_CR28","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2023","unstructured":"Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes & Diseases. 2023;10(4):1367\u2013401. https:\/\/doi.org\/10.1016\/j.gendis.2022.02.007.","journal-title":"Genes & Diseases"},{"issue":"2","key":"2244_CR29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1158\/2159-8290.CD-13-0197","volume":"4","author":"SL Kerns","year":"2014","unstructured":"Kerns SL, Ostrer H, Rosenstein BS. Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy. Cancer Discov. 2014;4(2):155\u201365. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0197.","journal-title":"Cancer Discov"},{"issue":"3","key":"2244_CR30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.12788\/jcso.0178","volume":"14","author":"SA Alsirafy","year":"2016","unstructured":"Alsirafy SA, Al-Alimi KA, Thabet SM, Al-Nabhi A, Aklan NA. Voluntary reporting to assess symptom burden among Yemeni cancer patients: common symptoms are frequently missed. J Community Support Oncol. 2016;14(3):117\u201321. https:\/\/doi.org\/10.12788\/jcso.0178.","journal-title":"J Community Support Oncol"},{"issue":"e2","key":"2244_CR31","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1136\/bmjspcare-2021-002999","volume":"13","author":"L Rojas-Concha","year":"2023","unstructured":"Rojas-Concha L, Hansen MB, Petersen MA, Groenvold M. Symptoms of advanced cancer in palliative medicine: a longitudinal study. BMJ Support Palliat Care. 2023;13(e2):e415\u201327. https:\/\/doi.org\/10.1136\/bmjspcare-2021-002999.","journal-title":"BMJ Support Palliat Care"},{"issue":"32","key":"2244_CR32","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1200\/jco.21.02017","volume":"40","author":"A Gilbert","year":"2022","unstructured":"Gilbert A, Piccinin C, Velikova G, Groenvold M, Kulis D, Blazeby J, et al. Linking the European Organisation for Research and Treatment of Cancer (EORTC) Item Library to the Common Terminology Criteria for Adverse Events (CTCAE). J Clin Oncol. 2022;40(32):3770\u201380. https:\/\/doi.org\/10.1200\/jco.21.02017.","journal-title":"J Clin Oncol"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-024-02244-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12955-024-02244-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-024-02244-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T02:23:41Z","timestamp":1711419821000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/s12955-024-02244-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2244"],"URL":"https:\/\/doi.org\/10.1186\/s12955-024-02244-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3888447\/v1","asserted-by":"object"}]},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]},"assertion":[{"value":"22 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted following the approval from the Danish Data Protection Agency (P-2021\u2013652) and the approval of each local ethics committee of countries involved. All participants signed the informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}